Home >> Behavioral Health >> Behavioral Health >> Baby Food >> Technology & Media >>

Corneal Neovascularization - Pipeline Review, H2 2012

Published: Dec-2012 | Format: PDF | Global Markets Direct | Number of pages: 36 | Code: MRS - 979

Global Markets Directs, 'Corneal Neovascularization Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Corneal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corneal Neovascularization. 

Corneal Neovascularization Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Corneal Neovascularization.
A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Corneal Neovascularization pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Corneal Neovascularization.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Corneal Neovascularization pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Corneal Neovascularization Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Corneal Neovascularization 7
Corneal Neovascularization Therapeutics under Development by Companies 9
Corneal Neovascularization Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Corneal Neovascularization Therapeutics - Products under Development by Companies 14
Corneal Neovascularization Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Corneal Neovascularization Therapeutics Development 16
Genentech, Inc. 16
Sirnaomics, Inc. 17
Corneal Neovascularization - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
IL-1Ra - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ranibizumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bevacizumab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
bevacizumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
pazopanib hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ranibizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
pSEC.siRNA.VEGFA Loaded Poly Lactic Co-Glycolic Acid Nanoparticles - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
STP-601 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Corneal Neovascularization Therapeutics - Drug Profile Updates 31
Corneal Neovascularization Therapeutics - Dormant Products 32
Corneal Neovascularization - Product Development Milestones 33
Featured News & Press Releases 33
Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure 33
Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth 34
Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye 34

Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables

Number of Products Under Development for Corneal Neovascularization, H2 2012 7
Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Genentech, Inc., H2 2012 16
Sirnaomics, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Corneal Neovascularization Therapeutics - Drug Profile Updates 31
Corneal Neovascularization Therapeutics - Dormant Products 32 
List of Figures

Number of Products under Development for Corneal Neovascularization, H2 2012 7
Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing